Phase 1/2 Open‑Label Study Of PF-06747775 (Epidermal Growth Factor Receptor T790M Inhibitor) In Patients With Advanced Epidermal Growth Factor Receptor Mutant (Del 19 or L858R ± T790M) Non‑Small Cell Lung Cancer

Trial Profile

Phase 1/2 Open‑Label Study Of PF-06747775 (Epidermal Growth Factor Receptor T790M Inhibitor) In Patients With Advanced Epidermal Growth Factor Receptor Mutant (Del 19 or L858R ± T790M) Non‑Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs PF 6747775 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 28 Oct 2017 Planned End Date changed from 1 Mar 2020 to 17 Dec 2021.
    • 28 Oct 2017 Planned primary completion date changed from 1 Oct 2019 to 2 Sep 2020.
    • 10 Oct 2017 Planned End Date changed from 1 Feb 2020 to 1 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top